Moreover, CCL7 blockade attenuated Ang II-induced hypertension and vascular remodeling in vivo, indicating that HIF1α or CCL7 blockade may be a potential means for treating vascular remodeling disease. The gene discussed is CCL7; the disease is Hypertension.